Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of sacubitril/valsartan vs olmesartan on blood pressure and glycolipid metabolism in hypertensive patients with type 2 diabetes
ChiCTR2200066428Phase 4Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in essential hypertension (2 arms), sponsored by Fuwai Hospital. Primary endpoint: Reduction of mean systolic blood pressure. Started Jan 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2200066428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066428.